Showing 2251-2260 of 6036 results for "".
- Johnson & Johnson Vision Presents New Myopia Progression and Contact Lens Findings at American Academy of Optometry Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-presents-new-myopia-progression-and-contact-lens-findings-at-american-academy-of-optometry-annual-meeting/2478387/Johnson & Johnson Vision announced clinical data from the latest in myopia research at the American Academy of Optometry’s virtual annual meeting (Academy 2020). Investigators will also reveal findings that demonstrate how Acuvue Oasys 1-Day with Hydraluxe Technology Contact Lenses redu
- Visus Therapeutics Launches and Announces Clinical Development Program for Novel Presbyopia Eye Drophttps://modernod.com/news/visus-therapeutics-launches-and-announces-clinical-development-program-for-novel-presbyopia-eye-drop/2478333/Visus Therapeutics announced its launch and clinical development program for a novel eye drop designed to restore the loss of near vision associated with presbyopia. Visus’ lead product candidate is Brimochol, a proprietary formulation that combines two FDA-approved pharmaceuticals: carbachol and
- FDA Grants Orphan Drug Designation for Neurophth Therapeutics’ Gene Therapy for LHONhttps://modernod.com/news/fda-grants-orphan-drug-designation-for-neurophth-therapeutics-gene-therapy-for-lhon/2478326/Neurophth Therapeutics announced that its leading candidate, NR082, was granted an orphan drug designation (ODD) by the FDA for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) associated with ND4 mutation. LHON is a maternall
- EnChroma Lens Technology Addresses Low Vision and Age-Related Eye Conditionshttps://modernod.com/news/enchroma-lens-technology-addresses-low-vision-and-age-related-eye-conditions/2478241/EnChroma announced the EnChroma Lx Lens Technology, a new lens series and eyewear designed for low vision and people 50+ with glare sensitivity, to address a rapidly growing category of visual challenges worldwide. EnChroma Lx Technology is specially engineered to sup
- AEYE Health Develops Advanced AI-Based Retinal Screening With Instant Resultshttps://modernod.com/news/aeye-health-develops-advanced-ai-based-retinal-screening-with-instant-results/2478232/AEYE Health has developed an AI-based retinal screening system that provides analysis and diagnostic results within 60 seconds. AEYE Health’s advanced machine learning and artificial intelligence technologies offer instant and accurate screening and analysis of the retina for the det
- Pandemic Will Leave Children With Less Access to Eye Care, New Survey Showshttps://modernod.com/news/pandemic-will-leave-children-with-less-access-to-eye-care-new-survey-shows/2478227/A survey conducted by the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) shows that pediatric specialists are struggling to keep their practices viable in the wake of the shutdown. As a result, ch
- PDL BioPharma Files With SEC For Potential Spin-Off of Lensarhttps://modernod.com/news/pdl-biopharma-announces-filing-of-a-form-10-registration-statement-with-the-sec-for-a-potential-spin-off-of-lensar-to-pdls-stockholders/2478207/PDL BioPharma announced that its majority owned medical device subsidiary, Lensar, has filed a registration statement on Form 10 with the Securities and Exchange Commission (SEC) relating to a potential spin-off of Lensar from PDL. “Preparations for a spin-off of Lensar to PDL’
- Regeneron Boosts Production Capacity for COVID-19 Antibody Cocktail Via Deal With Rochehttps://modernod.com/news/regeneron-boosts-production-capacity-for-covid-19-antibody-cocktail-via-deal-with-roche/2478176/Regeneron Pharmaceuticals said that the overall capacity to produce REGN-COV2, a two-antibody cocktail against COVID-19, will increase by at least 3.5 times under a development and manufacturing collaboration with Roche. As part of the deal, Regeneron will market REGN-COV2 in the US, with Roche r
- Diagnostic Market Sees New Demand Due to Effects of COVID-19https://modernod.com/news/diagnostic-market-sees-new-demand-due-to-effects-of-covid-19/2478150/Increasing demand for telehealth and mobile applications due to the COVID-19 pandemic has led manufacturers to scramble to add functionality and accessibility to existing devices and protection apparatuses or create new devices, according to a Market Scope report. Regulatory bodies and re
- Ocugen Receives Fourth FDA Orphan Drug Designation for Gene Therapy for the Treatment of Another Inherited Retinal Diseasehttps://modernod.com/news/ocugen-receives-fourth-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-another-inherited-retinal-disease/2478149/Ocugen announced the FDA granted the fourth Orphan Drug Designation (ODD) for OCU400 in the treatment of PDE6B gene mutation-associated retinal diseases. Retinitis Pigmentosa (RP) caused by PDE6B mutation is an inherited retinal dystrophy that leads to blindness by midlife and